PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase ... ( MIDLOTHIAN Va. March 10 /- PARI's...)

PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial

Date:3/10/2008

MIDLOTHIAN, Va., March 10 /PRNewswire/ -- PARI's LC STAR nebulizer and PRONEB Ultra II compressor are the exclusive delivery devices for Inspire Pharmaceuticals' (Nasdaq: ISPH) second Phase 3 clinical trial for a potential new cystic fibrosis treatment. PARI reusable nebulizers are considered the gold standard for clinical trials and are recommended in commercial sales including AstraZeneca's Pulmicort Respules, Sepracor's Xopenex and Brovana, Novartis' TOBI, Genentech's Pulmozyme, and DEY LP's Accuneb, Duoneb, and Perforomist.

"PARI has a strong track record of reliable and efficient, reproducible drug delivery, so it only makes sense that so many pharmaceutical companies look to PARI when developing new medications," said Lisa Cambridge, director of Clinical Development at PARI Respiratory Equipment. "Our LC STAR is a fine particle nebulizer that enables delivery of aerosols to the smaller airways of the lungs -- beneficial for successful respiratory therapies."

Known as TIGER-2, Inspire's second pivotal Phase 3 clinical trial with denufosol tetrasodium inhalation solution is beginning enrollment in the U.S. and Canada with patients age 5 years and older. The use of standard CF maintenance therapies is permitted during the trial, and additional information is available at http://www.inspirepharm.com.

The combination of PARI's LC STAR nebulizer and PRONEB Ultra II compressor provides for a quick treatment with high efficiency and minimal medication waste.

It is hoped that denufosol could be the first early intervention therapy available to CF patients that affects an early step in the progression of the disease. Denufosol for the treatment of cystic fibro
'/>"/>

SOURCE PARI Respiratory Equipment, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Post Your Comments:

(Date:11/25/2009)... , PRINCETON, N.J., Nov. 25 /PRNewswire-FirstC...cal stage pharmaceutical company committed to disc...s to treat viral infections, reported financial re.... At September 30, 2009 Pharmasset held $58.4 mill...tments. ,, Pipeline Update and 2009 Highlight...

(Date:11/25/2009)..., EXTON,Pa.,Nov.25/PRNewswire/--BioTrendsResearchG...Stelara report,thefirstinamulti-phasesyndicatedma...o-Biotech,sStelara,fromproductlaunchthroughthefirs...esquantitativeinformationfrom75uniqueDermatologist...tsassesstrialanduseofStelara,obstaclestouse,typica...

(Date:11/25/2009)... , COLLEGE PARK, Md., Nov. 25 /PRNewswire-USN...developing a shaving cream-like foam that stops se...Most Promising Security Idea category of the Globa...nce today. ,, Selected from more than 100 entri...their invention at the GSC Security Summit confere...

[0] Pharmasset Reports Fiscal Year End 2009 Financial Results [0] Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High [0] Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam

... SHPGY), the global specialty biopharmaceutical co...ientific data on its Attention Deficit,Hyperactivi...mesylate,methylphenidate transdermal system and th...A review, guanfacine extended release, at the Amer...to be held May 3rd to 8th in,Washington, D.C., "S...

...st-ever,pro-healing stent, OrbusNeich,s Genous Bio... at next month,s 16th Annual Scientific Congress o... for May 3 at the Sheraton Hong Kong Hotel, the on...ess by the symposium,s chairperson, Tak Fu Tse, M....ng Kong, from 1:30 p.m.-1:35 p.m., -- The latest ...

Other Medicine Technology:Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting 2 Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting 3 Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting 4 Clinical Impact of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology 2

Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting Clinical Impact of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology

(Date:11/27/2009)...ov. 27 /PRNewswire/ - Uploadable USB pedometers ma... wellness. A combination of advanced accelerometer...ng a long term concern over the accuracy of self-r...e and reward improved participation in a fitness p...e first wellness suppliers to integrate this techn...

(Date:11/27/2009)...ewswire-USNewswire/--Consideredahighlyriskyandcont...transplantationisnowalife-savingmainstreamoperatio...heWinspearOperaHouseinDallasonNov.11.Leaderscameto...he25thanniversaryofBaylorRegionalTransplantInstitu...heUnitedStates. ,, Itwas25yearsagothatBaylorHea...

(Date:11/27/2009)...Y., Nov. 27 Preventing ...and fortunately every year, new vaccines are being... vaccines boost immunity for the same period of ti...s, needed to keep immunity strong? ,, In this...merican Academy of Pediatrics, Michael Pichichero ...

(Date:11/27/2009)..., Israel, Nov. 27 Shamir... ), a leading provider of innovative products and ...d today that its board of directors had declared a...S$ 10 million (approximately NIS 37.62 million bas... exchange), or approximately US$ 0.609 (approximat...

(Date:11/27/2009)...low-emission vehicles may reduce future disease bu...7 (HealthDay News) -- Encouraging city dwellers to...r much greater public health benefits than increas... have found. , The study compared the projected...transport scenarios for London, England, and Delhi...

Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2 Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2 Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3 Health News:Why Some Vaccines May Require A Booster 2 Health News:Why Some Vaccines May Require A Booster 3 Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2 Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3 Health News:More Foot Power, Less Car Pollution Best for Health 2

[0] New USB technology adds accountability and convenience to wellness programs [0] Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary [0] Why Some Vaccines May Require A Booster [0] Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend [0] More Foot Power, Less Car Pollution Best for Health

...l Leader in Pregnancy and Baby Health Updates Imag...HITE PLAINS, N.Y., Jan. 15 The March of,Dimes tod... health of all,babies - those born healthy as well...ding print, television, radio, and,outdoor; new an...

...NCISCO, Jan. 15 The American Academy of,Ophthalmo...olkman, MD,whose research on angiogenesis inhibito...diseases and other illnesses that involve excessiv...kins, Jr., MD, executive vice president for,the Ac...

...ound those taking tablets had 47% higher risk of c... (HealthDay News) -- The calcium tablets taken by ...isk of osteoporosis may be contributing to an incr...ata from other recent studies showing an upward tr...

...T, N.J., Jan. 15 TeamStaff, Inc.,(Nasdaq: TSTF )...tive,staffing services, today announced its financ...07. TeamStaff,s revenues from continuing operation...ations for the three months ended September 30, 20...

..., Wis., Jan. 15 The Wisconsin Physicians Service,...waukee County today to,stop Aurora Health Care fro...with HealthEOS by MultiPlan, an independent primar...et face,to face with Aurora and HealthEOS to resol...

... winning Children,s Show SeeMore,s Playhouse(TM) d...lessons to kids, WASHINGTON, Jan. 15 The America... release the groundbreaking new,children,s safety ... into programming designed to teach children how t...

March of Dimes Delivers a New Look American Academy of Ophthalmology Mourns Loss of Judah Folkman, MD, Pioneering Researcher Calcium Supplements Could Raise Heart Risks in Postmenopausal Women TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS American Red Cross Partners With Safety4Kids(R) to Debut Children's Fire Safety DVD

...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...

Medicine Products:

Noradrenaline, Plasma Nonspecific Esterase Stain Nocardia Susceptibility Panel NMR LipoProfile

PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase ...( MIDLOTHIAN Va. March 10 /- PARI's...),Health